Skip to content

Advertisement

  • Correction
  • Open Access

Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

  • 1, 2Email author,
  • 2,
  • 3,
  • 2,
  • 4,
  • 3,
  • 5,
  • 3 and
  • 6, 7
BMC ImmunologyBMC series – open, inclusive and trusted201718:45

https://doi.org/10.1186/s12865-017-0228-6

  • Received: 20 September 2017
  • Accepted: 21 September 2017
  • Published:

The original article was published in BMC Immunology 2017 18:42

Erratum

After publication of the original article [1], the authors noticed that the percentages in Table 2 were incorrect.
Table 2

Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children

Adverse events

Incidence (per 100 children)

Vaccine dose

P-value

(1st and 2nd dose comparison)

P-value

(2nd and 3rddose comparison)

1st dose

(2 months)

N = 373

2nddose

(4 months)

N = 372

3rddose

(6 months)

N = 374

Swelling

79(21.2)

50(13.4)

48(12.8)

0.003

0.068

Redness

50(13.4)

30(8.1)

43(11.5)

0.026

0.679

Pain

190(50.9)

143(38.4)

62(16.6)

0.001

0.162

Mild fever

45(12.1)

33(8.9)

63(16.8)

0.068

<0.001

High fever

1(0.3)

0(0)

0(0)

0.388

NA

Drowsiness

83(22.3)

72(19.4)

70(18.7)

0.310

0.725

Anorexia

65(17.4)

51(13.7)

52(13.9)

0.126

1

Restlessness

35(9.4)

115(30.9)

119(31.8)

<0.001

0.766

Vomiting

16(4.3)

19(5.1)

17(4.5)

0.510

0.510

Long-term crying

24(6.4)

16(4.3)

22(5.9)

0.210

0.510

Encephalopathy

0(0)

0(0)

0(0)

NA

NA

Convulsion

0(0)

0(0)

0(0)

NA

NA

History of convulsion

0(0)

1(0.3)

2(0.5)

0.387

0.488

Family history of convulsion

0(0)

14(3.8)

6(1.6)

<0.001

0.074

NA not applicable

The correct version of Table 2 is published in this erratum.

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
(2)
Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
(3)
Deputy for Health, Hamadan University of Medical Sciences, Hamadan, Iran
(4)
Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
(5)
Center for Communicable Diseases Control, Ministry of Health, Tehran, Iran
(6)
Department of Communication Studies, Ghent University, Ghent, Belgium
(7)
Faculty of Social Sciences, University of Antwerp, Antwerp, Belgium

Reference

  1. Karami M, et al. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran. BMC Immunol. 2017;18:42. doi:10.1186/s12865-017-0226-8.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement